Here is a bit of the Reuters reprint; but Pantarhei chief executive officer Coelingh Bennink -- a former Organon executive -- was not immediately available for comment (he is an ex-Schering-Plough guy, through the Organon to SP connection):
. . . .Pantarhei Bioscience director Herjan Coeling Bennink, told the paper that Pantarhie can make the proposal as a result of backing from international private equity investors.
No financial details were provided. The private equity investors were not named either.
Merck said in September it had postponed the closure of Organon's R&D activities in the Netherlands while it negotiated on potential alternatives, including a sale. . . .
We'll keep you posted. [Outage abated.]